Psoriasis Clinical Trial
Official title:
Studies of the Pathogenesis and Natural History of Psoriatic Arthritis
This study will examine the genetic and immune factors involved in the cause and development
of psoriatic arthritis-a disease of both the skin and joints. It will describe the medical
features and natural course of the disease and determine participants' eligibility for
experimental treatment protocols.
Patients with known or suspected psoriatic arthritis 5 years of age and older and their
relatives may enroll in this study. Patients will be evaluated with a medical history and
physical examination, electrocardiogram, blood tests and X-rays. Additional procedures may
include:
1. Leukapheresis-Collection of white blood cells for genetic analysis. Whole blood is
collected through a needle placed in an arm vein. The blood circulates through a
machine that separates it into its components. The plasma is removed and the cells are
returned to the body through a second needle placed in the other arm.
2. Skin biopsy-Removal of a small skin sample for microscopic analysis. An area of skin is
numbed with an anesthetic and one to three small circular portions (about 1/4 inch in
diameter) are cut and removed.
3. Joint aspiration-Removal of a small sample of synovial fluid (lubricating joint fluid).
An area of skin around the biopsy site is numbed with an anesthetic, and a needle is
inserted into the joint to pull out a small fluid sample.
4. Synovial needle biopsy-Removal of a small sample of synovial tissue (tissue lining the
joint). An area of skin around the biopsy site is numbed with an anesthetic and a large
needle is inserted into the joint. A smaller needle attached to a syringe is then
placed inside the larger needle and small pieces of synovial tissue are removed.
5. Genetic studies-Saliva and blood samples will be collected for gene testing. Saliva is
collected by rinsing the mouth with a tablespoon of salt water and spitting into a test
tube.
Patients will be followed once or twice a year and may be evaluated for participation in an
experimental treatment study.
Participating relatives of patients will fill out a brief medical history questionnaire and
provide a DNA sample (blood sample or tissue swab from the inside of the cheek).
Patients with known or suspected psoriatic arthritis will be evaluated at the Clinical Center. Studies will include characterization of the clinical and laboratory features of the disease, research studies of the natural history and pathogenesis, genetic studies, and determination of the patient's eligibility to enter experimental therapeutic protocols. Patients may be asked to contribute blood, skin or synovial membrane samples for immunologic and genetic research studies. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |